Barely Significant
← all excerpts

Emerging treatments for Sjögren's disease: promising drugs on the horizon.

RMD Open · 2026 · PMC13295977 · PMID 42342283

Europe PMCDOI
1
hedged sentence
0.0160
closest p · 0.3× alpha
0.0160
boldest claim

The sentences

showed a trendp=0·016actually significant
In patients with high symptom burden, the ESSPRI total score showed a trend towards improvement with iscalimab 600 mg at week 24 with dryness (LS mean treatment difference –1.0 (95% CI –1.8 to –0.2); p=0·016) and fatigue (LS mean treatment difference –0.8 (–1.7 to 0.1); p=0·067) being the main drivers of improvement.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.